Premium
Molecular profiling as a novel tool to predict response to interferon‐α2 in MPNs: The proof of concept in early myelofibrosis
Author(s) -
Hasselbalch Hans Carl
Publication year - 2017
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.30676
Subject(s) - myelofibrosis , medicine , interferon , oncology , immunology , bone marrow
High‐risk mutations are associated with poor response to interferon‐α2. Early treatment with interferon‐α2 is recommended in patients who have early myelofibrosis without high‐risk mutations. See also pages 2680‐7.